Who Paid My Doc
A Phase I, Multi-Centre, Open-Label, Single Dose Escalation Study to E
Research payments
$10,146,259
Through program year 2025, $10,146,259 in research payments was reported against A Phase I, Multi-Centre, Open-Label, Single Dose Escalation Study to E, across 118 payments, paid by ViiV Healthcare Company.
- Paid by
- ViiV Healthcare Company
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $5,276,517 | 19 |
| 2024 | Research | $2,132,926 | 30 |
| 2023 | Research | $1,830,017 | 60 |
| 2022 | Research | $906,799 | 9 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
5 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.